FDA's drug and biologic centers each produced a novel approval last week, with Pfizer Inc.'s Eucrisa and Vericel Corp.'s Maci.
Eucrisa (crisaborole), an atopic dermatitis treatment that came from Pfizer's acquisition of Anacor Pharmaceuticals Inc
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?